FDA Inspection 1049402 — BioAgilytix
The FDA completed an inspection of BioAgilytix on Mar 2, 2018 in Hamburg. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Mar 2, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Hamburg (Germany)
Additional details
Bioanalytical BA/BE